2018 Jun 6
Shengjing Hospital of China Medical University, China
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. https://www.ncbi.nlm.nih.gov/pubmed/29885638
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers.
A promising treatment in immune-related diseases and cancer
A promising treatment in immune-related diseases and cancer
https://www.eboro.cz
Re: A promising treatment in immune-related diseases and can
At least the publishers gave us one of the paper's figures.
https://www.sciencedirect.com/science/a ... via%3Dihub
https://www.sciencedirect.com/science/a ... via%3Dihub
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1501 Views
-
Last post by DIM
-
- 0 Replies
- 1081 Views
-
Last post by Petr75
-
- 1 Replies
- 1159 Views
-
Last post by NHE
-
- 0 Replies
- 1983 Views
-
Last post by Tif
-
- 3 Replies
- 5022 Views
-
Last post by NHE
-
- 5 Replies
- 14499 Views
-
Last post by gibbledygook
-
- 1 Replies
- 1567 Views
-
Last post by ElliotB
-
- 0 Replies
- 1086 Views
-
Last post by DIM
-
- 5 Replies
- 2502 Views
-
Last post by Jaded